# US 2012/0231070 A1 · Sustained-release liposomal anesthetic compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231070 A1
- Document ID: US20120231070A1
- Status: Published application
- Kind: A1
- Application number: 13/476,823
- Filed: 2012-05-21
- Published: 2012-09-13
- Earliest claimed: 1997-09-18
- Assignees: Pacira Pharmaceutical, Inc.
- Inventors: Sinil Kim; Taehee Kim; Sharad Murdande
- Web page: https://patentgrep.com/patent/US20120231070A1

## CPC

- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 23/02: Local anaesthetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a) a multivesicular liposome comprising
at least one type of amphipathic lipid, and
at least one type of neutral lipid; and
b) an aqueous phase comprising
polyhydroxy carboxylate salts and di- or tri-protic mineral salts of amide-type anesthetics,
wherein the aqueous phase is encapsulated within the multi vesicular liposome.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the aqueous phase further comprises hydrochloric acid.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amphipathic lipid is provided in admixture with cholesterol, plant sterols, or combinations thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the di- or tri-protic mineral salts of the amide-type anesthetics are selected from the group consisting of sulfates, phosphates, and combinations thereof.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the polyhydroxy carboxylate salts of the amide-type anesthetics are selected from the group consisting of glucuronate, gluconate, tartarate, and combinations thereof.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amphipathic lipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, sphingomyelins, lysophosphatidylcholines, lysophosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, phosphatidic acids, cardiolipins, diacyl dimethylammonium propanes, and stearylamines.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the neutral lipid is selected from the group consisting of triglycerides, diglycerides, ethylene glycols, and squalene.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amide-type anesthetic is a xylidide.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the xylidide is selected from the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine, pyrrocaine, prilocaine and stereoisomers thereof.

### Claim 10 (depends on 8)

The pharmaceutical composition of claim 8, wherein the xylidide has the following structure:
wherein R1 is a secondary or tertiary alkyl amine or a secondary or tertiary alkylene amine, R2 is hydrogen, alkyl or alkylene which further links to R1, R3 is an alkyl substituted phenyl substituent.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein R1 and R2 form a substituent selected from the group consisting of N-alkyl piperidine, and N-alkyl pyrrolidine.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein R3 is 2,6-dimethylphenyl substituent.

### Claim 13

A process for preparing a multivesicular liposome-encapsulated anesthetic composition, the process comprising:
a) forming a “water-in-oil” type emulsion from a first aqueous phase and a volatile organic phase, wherein the first aqueous phase comprises
polyhydroxy carboxylate salts and di- or tri-protic mineral salts of amide-type anesthetics,
and the volatile organic phase comprises
a volatile organic solvent,
at least one type of amphipathic lipid, and
at least one type of neutral lipid;
b) dispersing the “water-in-oil” type emulsion into a second aqueous phase to form solvent spherules; and
c) removing the volatile organic solvent from the solvent spherules to form a multivesicular liposome-encapsulated amide-type anesthetic suspended in the second aqueous phase.

### Claim 14 (depends on 13)

The process of claim 13, wherein the amide-type anesthetic is a xylidide.

### Claim 15 (depends on 14)

The process of claim 14, wherein the xylidide is selected from the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine, pyrrocaine, prilocaine and stereoisomers thereof.

### Claim 16 (depends on 1)

A method of locally anesthetizing a subject, the method comprising subcutaneously, intracutaneously, or via a nerve block, injecting the pharmaceutical composition of claim 1 into a subject in need of anesthetization.

### Claim 17 (depends on 16)

The method of claim 16, wherein the amide-type anesthetic is a xylidide.

### Claim 18 (depends on 17)

The method of claim 17, wherein the xylidide is selected from the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine; pyrrocaine, prilocaine and stereo isomers thereof.

### Claim 19

A method of increasing drug loading in multivesicular liposomes by converting an amide-type anesthetic into a binary salt mixture wherein the two counterions are derived from a polyhydroxy carboxylic acid and a di- or tri-protic mineral acid.

### Claim 20 (depends on 19)

The method of claim 19, wherein the polyhydroxy carboxylic acid is selected from the group consisting of sulfuric acid, phosphoric acid, and combinations thereof.

### Claim 21 (depends on 19)

The method of claim 19, wherein the di- or tri-protic mineral acid is selected from the group consisting of sulfuric acid, phosphoric acid, and combinations thereof.

### Claim 22 (depends on 19)

The method of claim 19, wherein the amide-type anesthetic is a xylidide, selected from the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine, pyrrocaine, prilocaine and stereoisomers thereof.
